Alzheimer’s

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease

ILAP Designation accelerates patient access and commercialization  MIAMI, APRIL 5, 2023 (GLOBE NEWSWIRE) – ADvantage Therapeutics, Inc. (“ADvantage” or “the…

2 years ago

MetAlert, Inc. Selects Pod Group’s ENO ONE eSIM Solution to Connect “SmartSole” Healthcare Application

Mission-Critical GPS SmartSole Allows Users to Track the Whereabouts of Loved Ones with Alzheimer’s and Autism  Cambridge, UK, October 26th…

2 years ago

Treating Alzheimer’s: Is It Really an Autoimmune Disease?

Although Alzheimer’s is still listed as an incurable neurodegenerative disease, medical science has come a long way in terms of…

2 years ago